For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

such as enzalutamide and abiraterone, have validated the androgen receptor and secondary androgen production as crucial targets in metastatic castration-resistant prostate cancer (mCRPC).

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Devaki Surasi discussing combination sequencing for PSMA-based therapy in advanced disease. Dr. Surasi started with ...

Intravenous; mCRPC: Metastatic castration-resistant prostate ... Abiraterone acetate plus prednisone and enzalutamide improve overall survival (OS) and radiological progression-free survival ...